Home › Trial NCT03188328
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
- Trial IDNCT03188328
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorAlfasigma S.p.A.
- Enrollment3
- Start date2017-08-07
- ConditionsInoperable Solid Tumors or Lymphomas
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.